Every episode of RealTalk MS features updates and reports about emerging science. And, as you listen, some of you may wonder, 'When will these scientific achievements benefit me? When will these breakthroughs and advancements make their way from the laboratory workbench to the clinic?'   That's exactly what the panel of MS experts who comprise the International Advisory Committee on Clinical Trials in MS are proposing in a new framework that leverages what scientists are continuing to learn and re-defines how we talk about MS, research MS, diagnose MS, and treat MS. 

The new framework being recommended by the committee is broadly outlined in a paper that was published about 8 weeks ago. Joining me to discuss what this proposed framework is all about is the paper's lead author, Professor Tanja Kuhlmann.

We're also talking about the new high-efficacy disease-modifying therapy that received its FDA approval last week.

We're sharing the details behind the FDA's approval of a Phase 3 clinical trial for Masitinib, an investigational therapy for treating progressive MS.

We'll tell you about Abata Therapeutics' first T-cell treatment candidate for treating progressive MS.

And you'll hear about the results of a study that compared the outcome of treating people living with secondary progressive MS with autologous hematopoietic stem cell transplantation (aHSCT) versus treatment by disease-modifying therapies.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: Experts recommend a new framework for researching, diagnosing, and treating MS  :22

FDA approves Ublituximab (Briumvi), an anti-cd20 disease-modifying therapy  1:12

FDA approves Phase 3 clinical trial for Masitinib as a treatment for progressive MS  4:35

Abata Therapeutics announces its first T-cell therapy candidate to treat progressive MS  7:20

Study shows aHSCT more effective than DMTs in treating secondary progressive MS  10:14

Professor Tanja Kuhlmann discusses a new framework for researching, diagnosing, and treating MS  13:51

Share this episode  26:37

Have you downloaded the free RealTalk MS app?  26:57

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/279

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

STUDY: Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis https://nejm.org/doi/full/10.1056/NEJMoa2201904

AB Science https://ab-science.com

RealTalk MS Episode 205: A Potentially Transformational Therapy for Progressive MS with Samantha Singer and Dr. Richard Ransohoff https://realtalkms.com/205

STUDY: Hematopoietic Stem Cell Transplantation in People with Active Secondary Progressive MS https://n.neurology.org/content/early/2022/12/21/WNL.0000000000206750

Take the iConquer MS Caregiver Survey https://realtalkms.com/caregiver

Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200

Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk

Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 279 Guest: Professor Tanja Kuhlmann

Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS

Privacy Policy